FINWIRES · TerminalLIVE
FINWIRES

$ZBH

30 stories mentioning ZBHUpdated 3d ago

Every FINWIRES story that references ZBH, newest first.

What are analysts saying about ZBH?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ZBH?

Insider Trading

Zimmer Biomet Holdings Insider Sold Shares Worth $295,050, According to a Recent SEC Filing

Chad F Phipps, Senior Vice President, Chief Legal & Corporate Affairs Officer, and Secretary, on September 04, 2026, sold 3,000 shares in Zimmer Biomet Holdings (ZBH) for $295,050. Following the Form 4 filing with the SEC, Phipps has control over a total of 65,231 common shares of the company, with 65,231 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1136869/000134667226000010/xslF345X05/form4-09092026_080951.xml

$ZBH
Wire

Bernstein Adjusts Price Target on Zimmer Biomet to $93 From $91

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $104.90, according to analysts polled by FactSet.Price: $96.82, Change: $-1.34, Percent Change: -1.37%

$ZBH
Wire

Rothschild & Co. Redburn Adjusts Price Target on Zimmer Biomet to $117 From $115

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $104.90, according to analysts polled by FactSet.Price: $96.82, Change: $-1.34, Percent Change: -1.37%

$ZBH
Wire

UBS Adjusts Price Target on Zimmer Biomet to $120 From $115, Maintains Buy Rating

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $104.90, according to analysts polled by FactSet.Price: $97.26, Change: $-0.91, Percent Change: -0.92%

$ZBH
Wire

Baird Adjusts Price Target on Zimmer Biomet to $104 From $92, Maintains Neutral Rating

Zimmer Biomet (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.Price: $97.77, Change: $+1.96, Percent Change: +2.05%

$ZBH
Wire

RBC Capital Raises Zimmer Biomet Price Target to $110 From $101

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.Price: $97.77, Change: $+1.96, Percent Change: +2.05%

$ZBH
Wire

Piper Sandler Raises Zimmer Biomet Price Target to $100 From $93

Zimmer Biomet (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.Price: $97.69, Change: $+1.88, Percent Change: +1.96%

$ZBH
Wire

BMO Capital Adjusts Zimmer Biomet Price Target to $96 From $95, Maintains Market Perform Rating

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.Price: $97.89, Change: $+2.08, Percent Change: +2.17%

$ZBH
Wire

Evercore ISI Adjusts Price Target on Zimmer Biomet to $115 From $110, Maintains Outperform Rating

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $97.21, according to analysts polled by FactSet.Price: $97.89, Change: $+2.08, Percent Change: +2.17%

$ZBH
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.4%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Iqvia (IQV) shares surged 13% after it reported a year-over-year increase in Q2 adjusted earnings and revenue. The company also raised its 2026 outlook.GSK (GSK) shares advanced 3.3% after it posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.Seer (SEER) shareholders Bradley Radoff and Michael Torok said Tuesday they have submitted their fourth non-binding proposal to buy the company, raising their offer to $2.55 per share in cash. Seer shares jumped past 9%.Zimmer Biomet (ZBH) shares climbed 3.7% after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.

$GSK$IQV$SEER$ZBH
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.4%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Zimmer Biomet (ZBH) shares climbed 3.9% after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.

$ZBH
Wire

Zimmer Biomet Shares Rise After UBS Upgrade

Zimmer Biomet (ZBH) shares rose 4.2% in Tuesday trading after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.Trading volume stood at over 2 million shares compared with a daily average of about 2.3 million.Price: $95.34, Change: $+3.27, Percent Change: +3.55%

$ZBH
Research

UBS Upgrades Zimmer Biomet Holdings to Buy From Sell, Adjusts Price Target to $115 From $89

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $96.95, according to analysts polled by FactSet.Price: $97.15, Change: $+5.08, Percent Change: +5.52%

$ZBH
Research

BMO Capital Initiates Coverage on Zimmer Biomet With Market Perform Rating, $95 Price Target

Zimmer Biomet (ZBH) has an average rating of hold and mean price target of $95.50, according to analysts polled by FactSet.

$ZBH
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira shares rose 1%, and Zimmer fell past 6%.Unicycive Therapeutics (UNCY) shares tumbled 40% after it said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in people with chronic kidney disease on dialysis.AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US House over whether clinical trials conducted in China may have contributed to the country's military capabilities, Reuters reported. AbbVie shares were down 1.3%, and Merck shed nearly 1%.Align Technology (ALGN) shares fell 3% after the European Commission said Tuesday it has opened an antitrust probe to determine whether the company has violated EU competition rules by tying its dental clear aligners to its intra-oral scanners in the European Economic Area.

$ABBV$ALGN$MRK$PCRX$UNCY$ZBH
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira shares rose 1%, and Zimmer fell past 6%.

$PCRX$ZBH
Wire

Top Midday Decliners

Unicycive Therapeutics (UNCY) said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in patients with chronic kidney disease on dialysis.The letter relates to deficiencies previously identified at third-party manufacturing vendor, the firm said, adding that the FDA inspection of third-party facility did not occur during the resubmission review.Shares sank 37% amid a surge in intraday trading volume to over 17.2 million from a daily average of about 907,000 shares.JPMorgan Chase (JPM), which is running a stock and note offering from Sable Offshore (SOC), has seen limited investor demand for a loan paying 15%, Bloomberg reported Tuesday, citing people familiar with the matter.Sable shares sank 46% as intraday trading volume catapulted to over 45.0 million from a daily average of about 3.8 million.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million.Zimmer shares dropped 7.5%, with intraday trading volume of over 2.31 million against a daily average of about 2.34 million.Price: $4.83, Change: $-2.87, Percent Change: -37.27%

$JPM$PCRX$SOC$UNCY$ZBH
Update: Equity Markets Rise Intraday, Poised for Strong Quarterly Gains
US Markets

Update: Equity Markets Rise Intraday, Poised for Strong Quarterly Gains

(Updates with latest market prices and developments.)US benchmark equity indexes were higher intraday, led by gains in the technology sector, and poised to close out a winning quarter and first half of the year.The Nasdaq Composite was up 1.4% at 26,172.6 after midday Tuesday -- the last trading session of June -- while the S&P 500 rose 0.7% to 7,495.2. The Dow Jones Industrial Average added 0.3% to 52,362.8, following a record-high close in the previous session.The S&P 500 and the Nasdaq were headed for their best quarter in six years, while the Dow was on track for its best quarterly gain since 2022, news outlets reported. The Dow was poised for its best first-half performance since 2021, while the S&P 500 and the Nasdaq were also higher, CNBC reported.Among sectors, tech paced the gainers intraday Tuesday with a 2.2% jump, while real estate saw the steepest decline.Within tech, chip-related stocks mainly led gains, with Intel (INTC) up 7.7%, among the top performers on the S&P 500. Nvidia (NVDA) rose 1.7%, the third-best performer on the Dow. Advanced Micro Devices (AMD), Sandisk (SNDK), and Marvell Technology (MRVL) were also notable gainers on the S&P 500.AeroVironment (AVAV) shares jumped nearly 19% as the drone maker overnight reported stronger-than-expected fiscal fourth-quarter results and issued an upbeat full-year revenue outlook at the midpoint.Zimmer Biomet (ZBH) shares were down 6.9% intraday Tuesday, the worst performer on the S&P 500.Sportswear giant Nike (NKE) and beer and wine company Constellation Brands (STZ) are expected to release their latest quarterly results after the closing bell Tuesday.West Texas Intermediate crude oil was down 1.4% at $69.75 a barrel intraday, while Brent slipped 0.3% to $72.95.WTI and Brent were headed for a steep decline for the month of June as oil prices sold off after the US and Iran agreed to a memorandum of understanding to end their war. In May, crude prices tumbled about 17%."Oil prices traded within a relatively tight range near recent lows while remaining on track for their biggest quarterly decline since the pandemic," Saxo Bank said in a report Tuesday.US special envoys Steve Witkoff and Jared Kushner, who are in Doha, will meet Qatari mediators, not Iranian officials, CNN reported, citing Qatar's Foreign Ministry.US Treasury yields were higher intraday, with the 10-year rate up 3.3 basis points at 4.41% and the two-year rate rising 2.2 basis point to 4.14%.In economic news, US consumer confidence edged higher in June as falling oil prices amid an extended US-Iran ceasefire eased inflation fears, the Conference Board said.US home price growth accelerated annually in April, though the value of homes continued to deteriorate in real terms as high inflation outpaced price gains, S&P Global (SPGI) division S&P Dow Jones Indices said.Gold was little changed at $4,039.40 per troy ounce, while silver climbed 2.1% to $59.86 per ounce.

Dow JonesNasdaq CompositeS&P 500$AMD$AVAV$INTC$MRVL$NKE$NVDA$SNDK$SPGI$STZ$ZBH
Asia Markets

Update: US Equity Indexes Rise as Semiconductors Lift Technology; Crude Oil Slips as Trump's Envoys in Qatar for Indirect Talks

(Updates with index/price moves, macroeconomic data, and company news from the first paragraph.)US equity indexes rose, with the S&P 500 and the Nasdaq Composite set to clock the biggest quarterly gains since Q2 of 2020 amid semiconductor-led gains in technology.The Nasdaq Composite jumped 1.3% to 26,154.1, and the S&P 500 rose 0.7% to 7,490.7 after midday Tuesday. The Dow Jones Industrial Average advanced 0.3% to 52,348.4, heading for the strongest first half in five years.Technology was the standout gainer intraday, followed by industrials. Real estate, consumer staples, and healthcare led the decliners.Of the top 20 stocks with a market capitalization of more than $200 billion, 17 were from the tech sector, according to data compiled by Finviz. Within those tech names, the majority were either semiconductors or semiconductor equipment and materials. The top gainer was Advanced Micro Devices (AMD), trading up 7.7%.Bernstein adjusted the price target for SanDisk (SNDK) shares to $3,000 from $1,700 while maintaining its outperform rating. Shares of SanDisk were up 7.6%, one of the S&P 500 and Nasdaq's top gainers.In geopolitical news, US envoy for the Middle East Steve Witkoff and President Donald Trump's son-in-law Jared Kushner are in Doha to meet Qatari mediators, CNN reported Tuesday, citing Qatar's Foreign Ministry spokesperson. The US duo will not meet with Iranian officials, the report said.The mediators are working as go-betweens for US-Iran talks, which won't include any high-level officials, Qatar's Foreign Ministry spokesman Majed al-Ansari said, according to an Associated Press report.The front-month global benchmark North Sea Brent slipped 1.1% to $73.12 per barrel, and the US West Texas Intermediate fell 1.3% to $69.84 per barrel.Most US Treasury yields rose, with the 10-year up 3.6 basis points to 4.41%. The two-year rate climbed 2.2 basis points to 4.13%.Gold futures edged up 0.1%% to $4,040.5, and silver futures jumped 2.7% to $59.77.In economic news, US job openings rose to 7.594 million in May, according to the Bureau of Labor Statistics, above the 7.296 million openings expected in a Bloomberg-compiled survey and up from the 7.585 million openings reported in April.The Conference Board's measure of consumer confidence rose to 91.2 in June from a downwardly revised 90.6 in May, below the 94.4 expected in a Bloomberg-compiled poll.The Institute for Supply Management's Chicago PMI fell to 56.7 in June from 62.7 in May, compared with the expected 55.1 reading in a Bloomberg-compiled survey.In company news, Air Products and Chemicals (APD) said Tuesday it will not proceed with the Louisiana Clean Energy Project because the expected financial returns do not meet stringent return criteria. The company also said it's finalizing a marketing and distribution agreement with Yara International for renewable ammonia from a green hydrogen project in Saudi Arabia. Shares of Air Products jumped more than 8%, the top gainer on the S&P 500.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Zimmer shares dropped 7.4%, the worst performer on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$AMD$APD$PCRX$SNDK$ZBH
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira BioSciences shares were up more than 3% and Zimmer Biomet stock declined by more than 1% pre-bell.Arcutis Biotherapeutics (ARQT) shares were up more than 1% after the company said the US Food and Drug Administration cleared an expanded use of its Zoryve cream to treat plaque psoriasis in children as young as 2 years old.Evotec (EVO) has expanded its Just-Evotec Biologics services with J.TRAIN, a new offering that lets biopharmaceutical companies use Evotec's manufacturing technology within their own facilities on a turnkey basis, the company said. Evotec shares were up more than 1% pre-bell.

$ARQT$EVO$IBB$PCRX$XLV$ZBH

Showing 1-20 of 30

Track with the FINWIRES app suite

FolioX
FolioX
Track ZBH in your portfolio
WheelAI
WheelAI
Analyze ZBH options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ZBH